Sharemaestro company-news research for Eli Lilly and Company (LLY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
MEX
Mexico
Measured evidence
Company news sentiment
LLY news sentiment
Eli Lilly and Company
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone58Neutral is 50
Constructive news tone
79/100 evidence confidence
100% direct company focus
33 current stories across 1 publishers
Current company news
News confirmed by price
Constructive news tone is drawn from 33 fresh independent stories, including 33 company-specific items across 1 publishers.
Latest source headline Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market finance.yahoo.com · 12 Aug 2026 17:29What supports the read
33 current stories are mapped specifically to LLY.
Cross-story agreement is 80/100, indicating a comparatively coherent tape.
Constructive news tone is being confirmed by positive weekly price action.
What tempers the read
Only 1 publisher currently contribute to the measured read.
58/100
Weighted toneConstructive news tone
79/100
Evidence confidencesolid confidence
100%/100
Company focus33 direct stories
80/100
Evidence agreement20/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth100
29.23 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness77
recency-weighted evidenceAgreement80
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive news tone is being confirmed by positive weekly price action.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment confirms active trendPositive but stretched
News subjects
What is shaping the score
Earnings6514 stories · 42%
Regulatory and legal468 stories · 24%
Market update675 stories · 15%
Analyst action603 stories · 9%
Deals and strategy722 stories · 6%
Macro sensitivity671 stories · 3%
Source mix
Where the evidence comes from
finance.yahoo.com5933 stories · 100%
Recurring subjects
Subjects appearing most often
Pharma17Earnings11Obesity9Clinical Trials9Fda Approval8Biotech8Healthcare6Revenue Growth5Oncology4Guidance4
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#3183Tone
finance.yahoo.comDirect company coverage
LLY Q2 Deep Dive: Key Products and Pipeline Expansion
Global pharmaceutical company Eli Lilly (NYSE:LLY)reported Q2 CY2026 results topping the market's revenue expectations , with sales up 47.7% year on year to $22.97 billion. The company's full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts' estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts' consensus estimates. Is now the time to buy LLY? Find out in our full research report (it's free for active Edge members). Eli Lilly (LLY) Q2 CY2026 Highlights: Revenue: $22.97 billion vs analyst estimates of $20.62 billion (47.7% year-on-year growth
DiabetesEarningsGuidanceObesityPharmaRevenue Growth
- Published
- 08 Aug 2026 21:25
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#3260Tone
finance.yahoo.comDirect company coverage
Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portf
Clinical TrialsFda ApprovalHealthcareOncologyPharmaShare Price
- Published
- 08 Aug 2026 21:16
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#3333Tone
finance.yahoo.comDirect company coverage
Novo Nordisk Stock Rises After GLP-1 Antitrust Win
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, the case was filed by Strive Specialties, which claimed the drugmakers unfairly limited access to compounded GLP-1 weight-loss drugs through exclusive telehealth partnerships. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator
AntitrustLawsuitObesity DrugsPharma
- Published
- 07 Aug 2026 19:52
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.